NEW YORK, Nov. 2, 2015 /PRNewswire/ -- Levi & Korsinsky, LLP announces that it has commenced an investigation of Tokai Pharmaceuticals, Inc. ("Tokai Pharmaceuticals" or the "Company") (NASDAQGM: TKAI) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.
On November 2, 2015, an article on Seeking Alpha was published alleging that, among other things, "Tokai's attempt at a Phase 3 trial is based on data from just 6 patients out of 87 in Phase 2, based on after-the-fact cherry picking of data" and that "insider selling has been rampant ahead of the pivotal trial results in 2016." Tokai Pharmaceuticals shares were down 12.67% on intraday trading on November 2, 2015. To obtain additional information about the investigation, go to:
or contact Joseph E. Levi, Esq. either via email at email@example.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
SOURCE Levi & Korsinsky, LLP